Pfizer’s decision to halt further marketing of Beqvez is further sign of the sparse patient interest in gene therapies for ...

Solid Biosciences (NASDAQ:SLDB – Free Report) had its price objective boosted by Chardan Capital from $15.00 to $16.00 in a report published on Wednesday morning,Benzinga reports. The brokerage ...

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...

One of the largest pharmaceutical companies in North Carolina is discontinuing a treatment produced in the state.

At UMass Chan Medical School, researchers, doctors, patients and biomedical executives voiced their concerns over cuts to NIH and Medicaid.

Clinical-stage drug development offers big rewards—and big risks. | This week on "The Top Line," we dive into several of the ...

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics ...

INSM posts wider-than-expected Q4 loss. It reiterates its 2025 sales outlook for Arikayce in the range of $405-$425 million.

Betty is a caregiver to three sons, Max, Rowen, and Charlie. Her oldest was diagnosed with Duchenne muscular dystrophy in 2010 at 4 years old. The other boys were diagnosed with the same in the ...